Journal article
The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics
Controlled clinical trials, v 22(5), pp 573-592
01 Oct 2001
PMID: 11578789
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The Correction of Myopia Evaluation Trial (COMET) is a multicenter, randomized, double-masked, controlled clinical trial evaluating whether there is a difference in the progression of myopia between children wearing progressive addition lenses (PALs) versus conventional single vision lenses (SVLs), as measured by cycloplegic autorefraction. Axial length, measured by A-scan ultrasonography, is an additional outcome measure. To meet the recruitment goal of 450 participants, eligible children ages 6–11 years (inclusive) with myopia in both eyes (spherical equivalent between
−1.25 diopters (D) and
−4.50 D, astigmatism ≤ 1.50 D, and anisometropia < 1.00 D) were recruited at four clinical centers between September 1997 and September 1998. Children who participated were assigned to receive PALs (Varilux Comfort with a +2.00 D addition) or SVLs. Measures include standardized cycloplegic autorefraction (Nidek ARK700A autorefractor), axial length (Sonomed A2500 ultrasound), subjective refraction (Marco TRS system), visual acuity (modified Early Treatment Diabetic Retinopathy Study protocol), accommodation (Canon R-1), and phoria (cover test and Maddox rod). Outcome measures are collected annually; adherence is assessed and prescriptions updated semiannually. Participants are being followed for at least 3 years. COMET enrolled 469 children. Their mean age is 9.3 years (range 6–11 years); 52% are female. COMET children are ethnically diverse, according to a self-report with 46% White, 26% African American, 14% Hispanic, and 8% Asian. Best-corrected visual acuity is better than 20/32 in both eyes. Baseline mean (±SD) cycloplegic refractive correction is
−2.38 D (±0.81) in the right eye and
−2.40 D (±0.82) in the left eye; mean (±SD) axial length is 24.1 mm (±0.7) in both eyes. Follow-up of these children will provide a first step in answering the important question of whether there are effective means to slow myopia progression. Study results should be applicable to a large proportion of children with myopia. The study will also provide useful information on myopia progression in children wearing conventional single vision lenses.
Control Clin Trials 2001;22:573–592
Metrics
Details
- Title
- The Correction of Myopia Evaluation Trial (COMET): Design and General Baseline Characteristics
- Creators
- Leslie Hyman - Stony Brook UniversityJane Gwiazda - New England College of OptometryWendy L. Marsh-Tootle - University of Alabama at BirminghamThomas T. Norton - University of Alabama at BirminghamMohamed Hussein - Stony Brook UniversityMitchell Scheiman - Pennsylvania College of Optometry (PCO)
- Publication Details
- Controlled clinical trials, v 22(5), pp 573-592
- Publisher
- Elsevier
- Number of pages
- 20
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pennsylvania College of Optometry (PCO)
- Web of Science ID
- WOS:000171103000009
- Scopus ID
- 2-s2.0-0034812480
- Other Identifier
- 991021900191304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy